Sandu [SANDUPHQ] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
Sandu
BSE
Loading...
Sun Pharmaceutical
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Sandu wins in 8 metrics, Sun Pharmaceutical wins in 11 metrics, with 0 ties. Sun Pharmaceutical appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sandu | Sun Pharmaceutical | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 30.23 | 37.88 | Sandu |
| Price-to-Book Ratio | 1.11 | 5.45 | Sandu |
| Debt-to-Equity Ratio | 1.14 | 3.26 | Sandu |
| PEG Ratio | N/A | -1.94 | N/A |
| EV/EBITDA | 15.29 | 24.14 | Sandu |
| Profit Margin (TTM) | 2.41% | 19.29% | Sun Pharmaceutical |
| Operating Margin (TTM) | 2.08% | 24.34% | Sun Pharmaceutical |
| EBITDA Margin (TTM) | 2.08% | 24.34% | Sun Pharmaceutical |
| Return on Equity | 3.69% | 15.08% | Sun Pharmaceutical |
| Return on Assets (TTM) | 2.78% | 11.87% | Sun Pharmaceutical |
| Free Cash Flow (TTM) | $104,000 | $119.44B | Sun Pharmaceutical |
| Dividend Yield | 1.61% | 1.26% | Sandu |
| 1-Year Return | -18.34% | -5.82% | Sun Pharmaceutical |
| Price-to-Sales Ratio (TTM) | 0.70 | 7.32 | Sandu |
| Enterprise Value | $447.85M | $3,703.34B | Sun Pharmaceutical |
| EV/Revenue Ratio | 0.67 | 6.89 | Sandu |
| Gross Profit Margin (TTM) | 58.93% | 79.58% | Sun Pharmaceutical |
| Revenue per Share (TTM) | $69 | $224 | Sun Pharmaceutical |
| Earnings per Share (Diluted) | $1.60 | $43.33 | Sun Pharmaceutical |
| Beta (Stock Volatility) | 0.20 | 0.31 | Sandu |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Sandu vs Sun Pharmaceutical Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sandu | 0.99% | 1.15% | -2.58% | -8.65% | -9.30% | -14.10% |
| Sun Pharmaceutical | -0.53% | 2.69% | -2.45% | -3.91% | -3.48% | -13.15% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sandu | -18.34% | -29.59% | 100.71% | 60.97% | 213.07% | 33.07% |
| Sun Pharmaceutical | -5.82% | 82.10% | 208.33% | 75.01% | 815.76% | 2,735.38% |
Performance & Financial Health Analysis: Sandu vs Sun Pharmaceutical
| Metric | SANDUPHQ | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹467.30M | ₹3.94T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 1,296 | 2,563,431 |
| 90 Day Avg. Volume | 2,398 | 2,041,608 |
| Last Close | ₹48.85 | ₹1,632.70 |
| 52 Week Range | ₹43.75 - ₹69.50 | ₹1,553.05 - ₹1,960.35 |
| % from 52W High | -29.71% | -16.71% |
| All-Time High | ₹86.00 (Apr 25, 2022) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -43.20% | -16.71% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.10% |
| Quarterly Earnings Growth | 0.34% | -0.20% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.19% |
| Operating Margin (TTM) | 0.02% | 0.24% |
| Return on Equity (TTM) | 0.04% | 0.15% |
| Debt to Equity (MRQ) | 1.14 | 3.26 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹43.77 | ₹300.99 |
| Cash per Share (MRQ) | ₹2.73 | ₹108.88 |
| Operating Cash Flow (TTM) | ₹5.35M | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹15.52M | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.61% | 1.26% |
| Last 12-Month Dividend | ₹0.80 | ₹21.00 |
Valuation & Enterprise Metrics Analysis: Sandu vs Sun Pharmaceutical
| Metric | SANDUPHQ | SUNPHARMA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 30.23 | 37.88 |
| Forward P/E | N/A | 50.23 |
| PEG Ratio | N/A | -1.94 |
| Price to Sales (TTM) | 0.70 | 7.32 |
| Price to Book (MRQ) | 1.11 | 5.45 |
| Market Capitalization | ||
| Market Capitalization | ₹467.30M | ₹3.94T |
| Enterprise Value | ₹447.85M | ₹3.70T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.67 | 6.89 |
| Enterprise to EBITDA | 15.29 | 24.14 |
| Risk & Other Metrics | ||
| Beta | 0.20 | 0.31 |
| Book Value per Share (MRQ) | ₹43.77 | ₹300.99 |
Financial Statements Comparison: Sandu vs Sun Pharmaceutical
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SANDUPHQ | SUNPHARMA |
|---|---|---|
| Revenue/Sales | ₹140.69M | ₹137.86B |
| Cost of Goods Sold | ₹57.79M | ₹28.15B |
| Gross Profit | ₹82.91M | ₹109.71B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹3.02M | ₹33.72B |
| EBITDA | ₹5.20M | ₹47.66B |
| Pre-Tax Income | ₹3.45M | ₹31.73B |
| Income Tax | ₹159,000 | ₹8.70B |
| Net Income (Profit) | ₹3.29M | ₹22.93B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SANDUPHQ | SUNPHARMA |
|---|---|---|
| Cash & Equivalents | ₹13.04M | ₹102.69B |
| Total Current Assets | ₹262.99M | ₹526.24B |
| Total Current Liabilities | ₹120.86M | ₹181.94B |
| Long-Term Debt | ₹4.19M | ₹3.58B |
| Total Shareholders Equity | ₹420.17M | ₹724.86B |
| Retained Earnings | N/A | ₹578.62B |
| Property, Plant & Equipment | ₹181.22M | ₹100.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SANDUPHQ | SUNPHARMA |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SANDUPHQ | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 1,296 | 2,563,431 |
| Average Daily Volume (90 Day) | 2,398 | 2,041,608 |
| Shares Outstanding | 9.66M | 2.40B |
| Float Shares | 3.45M | 1.04B |
| % Held by Insiders | 0.66% | 0.56% |
| % Held by Institutions | 0.00% | 0.25% |
Dividend Analysis & Yield Comparison: Sandu vs Sun Pharmaceutical
| Metric | SANDUPHQ | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹0.80 | ₹21.00 |
| Last 12-Month Dividend Yield | 1.61% | 1.26% |
| 3-Year Avg Annual Dividend | ₹1.02 | ₹14.67 |
| 3-Year Avg Dividend Yield | 1.12% | 0.46% |
| 3-Year Total Dividends | ₹3.05 | ₹44.00 |
| Ex-Dividend Date | Sep 19, 2024 | Jul 07, 2025 |